Alendronate alters osteoblast activities

References

• Delmas PD, Meunier PJ. The management of Paget's disease of bone. N Engl J Med. 1997;336:558–566.
   PubMed Web of Science ®Google Scholar
• McClung M, Harris ST, Miller PD, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2013;126:13–20.
   PubMed Web of Science ®Google Scholar
• Fleisch H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs. 1991;42:919–944.
   PubMed Web of Science ®Google Scholar
• Schenk R, Eggli P, Fleisch H, et al. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int. 1986;38:342–349.
   PubMed Web of Science ®Google Scholar
• Murad MH, Drake MT, Mullan RJ, et al. Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2012;97:1871–1880.
   PubMed Web of Science ®Google Scholar
• Stefanik D, Sarin J, Lam T, et al. Disparate osteogenic response of mandible and iliac crest bone marrow stromal cells to pamidronate. Oral Dis. 2008;14:465–471.
   PubMed Web of Science ®Google Scholar
• Khosla S, D. Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22:1479–1491.
   PubMed Web of Science ®Google Scholar
• Erviti J, Alonso A, Oliva B, et al. Oral bisphosphonates are associated with increased risk of subtrochanteric and diaphyseal fractures in elderly women: a nested case-control study. BMJ Open. 2013;3:e002091.
   Web of Science ®Google Scholar
• Vaishya R, Vaish A, Nadeem A. Bisphosphonate-induced atypical subtrochanteric femoral fracture. BMJ Case Rep. 2013;2013:bcr2013201931.
   PubMedGoogle Scholar
• Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115–1117.
   PubMed Web of Science ®Google Scholar
• Parfitt AM, Mundy GR, Roodman GD, et al. A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res. 1996;11:150–159.
   PubMed Web of Science ®Google Scholar
• Kimachi K, Kajiya H, Nakayama S, et al. Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis. Naunyn Schmiedebergs Arch Pharmacol. 2011;383:297–308.
   PubMed Web of Science ®Google Scholar
• Epstein MS, Wicknick FW, Epstein JB, et al. Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110:593–596.
   PubMed Web of Science ®Google Scholar
• Scheper MA, Badros A, Salama AR, et al. A novel bioassay model to determine clinically significant bisphosphonate levels. Support Care Cancer. 2009;17:1553–1557.
   PubMed Web of Science ®Google Scholar
• Acil Y, Moller B, Niehoff P, et al. The cytotoxic effects of three different bisphosphonates in-vitro on human gingival fibroblasts, osteoblasts and osteogenic sarcoma cells. J Craniomaxillofac Surg. 2012;40:229–235.
   PubMed Web of Science ®Google Scholar
• Saracino S, Canuto RA, Maggiora M, et al. Exposing human epithelial cells to zoledronic acid can mediate osteonecrosis of jaw: an in vitro model. J Oral Pathol Med. 2012;41:788–792.
   PubMed Web of Science ®Google Scholar
• Huang KC, Cheng CC, Chuang PY, et al. The effects of zoledronate on the survival and function of human osteoblast-like cells. BMC Musculoskelet Disord. 2015;16:355.
   PubMed Web of Science ®Google Scholar
• Bayram H, Kenar H, Tasar F, et al. Effect of low level laser therapy and zoledronate on the viability and ALP activity of Saos-2 cells. Int J Oral Maxillofac Surg. 2013;42:140–146.
   PubMed Web of Science ®Google Scholar
• Khan SA, Kanis JA, Vasikara S, et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res. 1997;12:1700–1707.
   PubMed Web of Science ®Google Scholar
• Huja SS, Beck FM. Bone remodeling in maxilla, mandible, and femur of young dogs. Anat Rec (Hoboken). 2008;291:1–5.
   PubMedGoogle Scholar
• Marolt D, Cozin M, Vunjak-Novakovic G, et al. Effects of pamidronate on human alveolar osteoblasts in vitro. J Oral Maxillofac Surg. 2012;70:1081–1092.
   PubMed Web of Science ®Google Scholar
• Simon MJ, Niehoff P, Kimmig B, et al. Expression profile and synthesis of different collagen types I, II, III, and V of human gingival fibroblasts, osteoblasts, and SaOS-2 cells after bisphosphonate treatment. Clin Oral Investig. 2010;14:51–58.
   PubMed Web of Science ®Google Scholar
• Sun J, Song F, Zhang W, et al. Effects of alendronate on human osteoblast-like MG63 cells and matrix metalloproteinases. Arch Oral Biol. 2012;57:728–736.
   PubMed Web of Science ®Google Scholar
• von Knoch F, Jaquiery C, Kowalsky M, et al. Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials. 2005;26:6941–6949.
   PubMed Web of Science ®Google Scholar
• Manzano-Moreno FJ, Ramos-Torrecillas J, De Luna-Bertos E, et al. High doses of bisphosphonates reduce osteoblast-like cell proliferation by arresting the cell cycle and inducing apoptosis. J Craniomaxillofac Surg. 2015;43:396–401.
   PubMed Web of Science ®Google Scholar
• Fromigue O, Body JJ. Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J Endocrinol Invest. 2002;25:539–546.
   PubMed Web of Science ®Google Scholar
• Reseland JE, Syversen U, Bakke I, et al. Leptin is expressed in and secreted from primary cultures of human osteoblasts and promotes bone mineralization. J Bone Miner Res. 2001;16:1426–1433.
   PubMed Web of Science ®Google Scholar
• Zhang J, Li T, Xu L, et al. Leptin promotes ossification through multiple ways of bone metabolism in osteoblast: a pilot study. Gynecol Endocrinol. 2013;29:758–762.
   PubMed Web of Science ®Google Scholar
• Sebastian-Ochoa A, Fernandez-Garcia D, Reyes-Garcia R, et al. Adiponectin and leptin serum levels in osteoporotic postmenopausal women treated with raloxifene or alendronate. Menopause. 2012;19:172–177.
   PubMed Web of Science ®Google Scholar
• Tariq S, Tariq S, Alam SS, et al. Effect of ibandronate therapy on serum homocysteine and leptin in postmenopausal osteoporotic females. Osteoporos Int. 2015;26:1187–1192.
   PubMed Web of Science ®Google Scholar
• Wehrhan F, Amann K, Mobius P, et al. BRONJ-related jaw bone is associated with increased Dlx-5 and suppressed osteopontin-implication in the site-specific alteration of angiogenesis and bone turnover by bisphosphonates. Clin Oral Investig. 2015;19:1289–1298.
   PubMed Web of Science ®Google Scholar
• Lechner J, von Baehr V. Chemokine RANTES/CCL5 as an unknown link between wound healing in the jawbone and systemic disease: is prediction and tailored treatments in the horizon? EPMA J. 2015;6:10.
   PubMed Web of Science ®Google Scholar
• Kamalakar A, Bendre MS, Washam CL, et al. Circulating interleukin-8 levels explain breast cancer osteolysis in mice and humans. Bone. 2014;61:176–185.
   PubMed Web of Science ®Google Scholar
• Kashii M, Hashimoto J, Nakano T, et al. Alendronate treatment promotes bone formation with a less anisotropic microstructure during intramembranous ossification in rats. J Bone Miner Metab. 2008;26:24–33.
   PubMed Web of Science ®Google Scholar